ABOUT NBRLBOSTON

NBRLBoston originated from E&E Bio-Research Lab (BRL), which started in 2006 at Innovative Incubation Center in NJIT nearby Princeton University by US scientists with more than 10 years of experience in established Bio-pharmaceutical companies.  At the beginning , the E&E BRL established the therapeutic antibody, Bio-specific fusion protein and immune cellular therapy technical platform, and developed the therapeutic antibody candidate and immune cellular drug at E&E BRL in NJIT. Later on, we expanded to develop several anti-tumor monoclonal antibody and gene drugs and anti-tumor cell drugs simultaneously at MCA Global BRL in the University of Pennsylvania Science Park in 2008.

In 2011, the team moved to Cambridge/Boston MA and continued to engage on developing anti-tumor immune therapy candidates by focusing on anti-solid tumor immune cellular drug and technology development (JaBioUS),  and anti-cancer immune gene and intrabody drugs development in New Bio-Research Lab Boston (NBRLBoston).  Since then, a variety of anti-cancer immune gene drug and intrabody candidates at NBRLBoston for the treatment of solid tumors and viral infection diseases have been developed. The anti-tumor gene drug candidates have finished both in vitro and in vivo animal evaluation, showing efficacious inhibition of solid tumor growth and safety in animal studies. In addition, NBRLBoston is  working on the discovery and development of mRNA/DNA gene and antibody fusion protein based candidates with T and NK cells combo immune therapy for anti-solid tumor and virus infection diseases .

Now, NBRLBoston is looking for investment to support the R&D projects in development of anti-solid tumor immune mRNA/DNA antibody fusion protein with T and NK cells drug  candidates to move to pre-clinical stage, and for the  preparation of CMC and IND ready anti-cancer therapy candidates in clinical studies.